New
SM
Clara Fargo
EBMT Clinical Research Quality Assurance Coordinator
I have finalised the demo for the ICH-GCP E6 R3 refresher course. Overall, I liked the content and the interface. I also want to thank Whitehall Train...
Inspection Readiness (Cross-GxP) Course & Certification
Intermediate
Watch Preview
4.7
★★★★★
97% Recommended
3 hours
198 active users
3 points
Watch Preview
Your Study Basket
Inspection Readiness (Cross-GxP)
| Total | |
🎁 FREE Bonus Included
eBookWorth £29— Yours FREE when you purchase today.
VAT is levied as per your country’s applicable rules and rates at checkout
Save more with a monthly or annual plan that includes this course
Secure Payment Service
Rest assured we use secure processes to protect your payment.
Secured by:
About
Inspection Readiness (Cross-GxP) training provides comprehensive knowledge of preparing for and managing regulatory inspections across GMP, GDP, GLP, and GCP environments. The course covers inspection planning, documentation readiness, data integrity, quality systems, regulatory expectations, inspection conduct, communication with inspectors, and continuous inspection readiness.
This Inspection Readiness (Cross-GxP) Training Course & Certification provides practical understanding of FDA, EU, MHRA, PIC/S, and international inspection expectations, inspection hosting, deficiency management, CAPA, inspection response writing, and continuous improvement practices to strengthen regulatory compliance and inspection confidence.
Who Should Enrol?
- Quality Assurance (QA) Professionals
- Quality Control (QC) Professionals
- Manufacturing and Production Personnel
- Warehouse and Distribution Professionals
- Clinical, Laboratory, and Research Personnel
- Regulatory Affairs and Compliance Professionals
- Auditors and Inspection Coordinators
- Anyone involved in GxP compliance, regulatory inspections, and quality systems
What you will learn
Understand the principles of inspection readiness across GMP, GDP, GLP, and GCP, including continuous compliance, inspection planning, and regulatory expectations.
Learn global regulatory inspection requirements from FDA, EU, MHRA, PIC/S, and other international authorities, including inspection processes and deficiency classifications.
Gain practical knowledge of inspection preparation, documentation readiness, data integrity, audit trails, inspection communication, and front room/back room management.
Understand inspection observations, root cause analysis, CAPA, inspection responses, and best practices for maintaining continuous inspection readiness.
Course Syllabus
- Why readiness matters and the cost of unreadiness
- The FDA, the EMA and national competent authorities, the MHRA and the PIC/S scheme
- The inspection lifecycle from notification to follow-up
- FDA outcomes: the Form 483, the Establishment Inspection Report and NAI/VAI/OAI; Warning Letters and import alerts
- EU/EEA outcomes: deficiencies graded critical/major/other and EudraGMDP
- MHRA (UK) outcomes: the post-inspection letter, compliance escalation and the Inspection Action Group
- Law versus guidance versus ICH/OECD standard — telling document types apart
- Aldbridge: the group, its four GxP operations and their regulators
- Inspection types: routine/surveillance, for-cause, pre-approval/pre-licence and product-specific
- Distant and remote assessments — what they are and where they fit
- Triggers and data-driven site-selection signals
- Building a regulatory-intelligence and horizon-scanning habit
- Treating statistics as time-bound and source-caveated
- Aldbridge: a for-cause trigger and a pre-approval inspection on the horizon
- ALCOA+ across paper and electronic records and all four GxPs
- Audit-trail and computerised-system evidence an inspector will expect
- Responding to a lawful data or records request completely, accurately and traceably
- FDA section 704(a)(4) advance records requests and Form FDA 4003
- Distant-assessment and remote-package responses
- Control, not concealment — comply with lawful requests; never obstruct, hide or alter
- Aldbridge: an FDA section 704(a)(4) advance request before a pre-approval inspection
- Preparing a GMP site: facility, pharmaceutical quality system, batch records and laboratories
- The recurring GMP citation themes: quality unit, investigations and OOS, written procedures, laboratory controls
- Running a GMP back-room evidence flow
- Data integrity in the GMP context
- Aldbridge Pharma: preparing the oral-solid-dose manufacturing site
- Preparing a GDP/wholesale operation: the Responsible Person, premises and temperature control
- Qualifying suppliers and customers (bona fides) and transport controls
- Falsified-medicines controls
- Evidencing GDP compliance to an inspector
- Aldbridge Distribution: a distant assessment of the WDA(H) hub by an EU competent authority
- Preparing a GLP test facility: test-facility management, the Study Director, the QA unit and the archive
- The study plan, raw data and specimen control
- Preparing a GCP sponsor, CRO and site and the Trial Master File
- FDA Bioresearch Monitoring (BIMO) inspections of sponsors, CROs, sites and IRBs
- Keeping the GLP and GCP frameworks distinct
- Aldbridge Labs and Aldbridge Clinical: a for-cause GLP trigger and a BIMO TMF gap
- Designing front-room and back-room roles and logistics
- Hosting professionally and answering questions honestly and precisely
- "I will find out and confirm" — a valid, professional answer
- Controlling documents and running daily wrap-ups during the inspection
- Aldbridge: setting up the front room and back room
- Interpreting and responding to a Form 483 or deficiency letter
- Writing an effective, CAPA-backed response and tracking commitments
- Escalation paths: Warning Letter, non-compliance statement, IAG referral and import alert
- Running a sustained readiness programme: mock inspections, metrics and management review
- A clean history is not proof of compliance and never guarantees the next outcome
- Aldbridge: a Form 483 with a data-integrity observation, the response and the CAPA
- Module 8 recap and knowledge checks
- Recap the eight modules of the course
- Draw out the five through-lines
- Restate the readiness-integrity disclaimer
- Offer a cross-GxP self-assessment and next steps
- 📘 Bonus:Inspection Readiness (Cross-GxP) eBook (Free with purchase)
Course Benefits
Free eBook
Get our exclusive eBook with every purchase - a complete companion guide to the course, yours to keep forever
CPD Points
Gain Continuing Professional Development (CPD) Points, accredited by The Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom. These can be used to count towards the distance learning element of any scheme that comes under the umbrella of The Academy of Medical Royal Colleges or any other scheme for which there is mutual recognition.
Certification
Receive a personal certificate to show your subject knowledge on course completion.
Affordable
You get excellent value through our cost-effective prices. We can also offer you group discounts on larger purchases.
Flexibility
The course saves you time through the convenience of online availability. This lets you complete the interactive course at your own comfort.
Keep Up to Date
You will stay up to date with the current inspection frameworks and their divergence across jurisdictions: the US FD&C Act section 704, including the section 704(a)(4) advance records request and Form FDA 4003; the FDA's final Remote Regulatory Assessments Q&A guidance (26 June 2025); 21 CFR Parts 210/211 (GMP), Part 58 (GLP) and Parts 312/50/56 with the BIMO programme (GCP); EudraLex Volume 4 (EU GMP), the EU GDP Guidelines (2013/C 343/01), and EU deficiency grading recorded in EudraGMDP; the EU–US Mutual Recognition Agreement, including EU reliance on FDA inspections conducted outside the US from 1 October 2025; PIC/S PE 009 and PI 041; MHRA GMP, GDP and data-integrity positions and UK escalation via the Inspection Action Group; the OECD Principles of GLP; and ICH E6 (GCP), Q9(R1) and Q10 — as our training courses are constantly monitored, reviewed and updated. Statistics and enforcement trends change, and drafts, pilots and consultations are flagged as NOT binding; positions were verified in July 2026 and must be re-verified against the source, for the relevant jurisdiction and discipline, before use.
Learn from Industry Experts
The course content is Whitehall Training editorial material, developed to reflect established cross-GxP inspection practice — how readiness is actually built and evidenced across GMP, GDP, GLP and GCP, and the failure modes that appear when a jurisdiction is left unstated or when inspection-week theatre is mistaken for a genuine state of control. It is built around a single fictional case study, the Aldbridge Life Sciences Group, with a GMP manufacturing site, a GDP distribution hub, a GLP non-clinical laboratory and a GCP clinical sponsor function, so that every readiness, data-request and response decision is one the learner can reason through. Laws, regulations and guidance are paraphrased and section-referenced; they are never reproduced, and nothing in the course is legal advice or a regulator endorsement.
Our Certified Customers
Learner Rating & Reviews
4.7
★★★★★★
Average Rating
536 global ratings
★★★★★
87.0%
★★★★★
5.0%
★★★★★
3.0%
★★★★★
3.0%
★★★★★
2.0%
Best Seller
